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Revascularization strategies in patients with STEMI and
MVD have been investigated in several trials. PRAMI
(Preventive Angioplasty in Acute Myocardial Infarction),
enrolling a total of 465 patients, demonstrated superiority
of immediate complete versus culprit lesion only
Table I. Current evidence of complete versus culprit lesion only revascularization in patients with ST-segment elevation myocardial infarction and
multivessel disease
Trial Year n Primary endpoint Follow-up
Primary endpoint in
complete versus
culprit-only
revascularization groups HR (95% CI) Comment
PRAMI(1) 2013 465 Cardiac death, non-fatal
myocardial infarction,
or refractory angina
23 months
(mean follow-up)
9.0% versus 23.0% 0.35 (0.21-0.58) Complete revascularization
during index procedure
CvLPRIT(2) 2015 296 All-cause death, recurrent
myocardial infarction,
ischemia-driven
revascularization,
and heart failure
12 months 10.0% versus 21.2% 0.45 (0.24-0.84) 2/3 of complete
revascularization during
index procedure
DANAMI-3-
PRIMULTI(3)
2015 627 All-cause death, non-fatal
reinfarction, and
ischemia-driven
revascularization of
non-infarct related arteries
>12 months
(median follow-up
27 months)
13.0% versus 22.0% 0.56 (0.38-0.83) FFR-guided PCI of
non-culprit arteries 2 days
after index procedure
COMPARE-
ACUTE(4)
2017 885 All-cause death, non-fatal
myocardial infarction,
revascularization, and
cerebrovascular events
12 months 7.8% versus 20.5% 0.35 (0.22-0.35) FFR-guided PCI of
non-culprit arteries
(84% during
index procedure)
COMPLETE(5) 2019 4041 Cardiovascular death
or myocardial infarction
3 years 7.8% versus 10.5% 0.74 (0.60-0.91) Randomization stratified
according to the intended
timing of non-culprit
lesion PCI
CI, confidence interval; FFR, fractional flow reserve; HR, hazard ratio; PCI, percutaneous coronary intervention.
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Volume 228revascularization in terms of cardiac death, non-fatal
myocardial infarction, or refractory angina at a mean
follow-up of 23 months.6 Similarly, CvLPRIT (Complete
versus Lesion-Only Primary PCI) showed in a total of 296
patients that index admission complete revascularization
as compared to culprit lesion only percutaneous coronary
intervention (PCI) significantly reduced the primary
endpoint, a composite of death, recurrent myocardial
infarction, heart failure, and ischemia-driven revascular-
ization at 12 months.7 These findings were supported by
DANAMI-3-PRIMULTI (Complete revascularization versus
treatment of the culprit lesion only in patients with ST-
segment elevation myocardial infarction and multivessel
disease). DANAMI-3-PRIMULTI included a total of 627
patients after successful primary PCI and provided
evidence that fractional flow reserve (FFR)-guided
complete revascularization as compared with no further
invasive intervention was associated with a reduced risk
of the composite endpoint of death, non-fatal myocardial
infarction, and ischemia-driven revascularization,
assessed when the last patient had been followed up for
1 year.8 In line with these findings, COMPARE-ACUTE
(Comparison Between FFR Guided Revascularization
Versus Conventional Strategy in Acute STEMI Patients
With MVD) demonstrated in 885 patients that FFR-guided
complete revascularization of non-infarct-related coro-
nary arteries as compared to culprit lesion only PCI
resulted in a lower risk of death, non-fatal myocardial
infarction, revascularization, and cerebrovascular eventsat 12 months.9 COMPLETE (Complete versus Culprit-
Only Revascularization Strategies to Treat Multivessel
Disease after Early PCI for STEMI) then demonstrated that
among patients with STEMI and MVD, complete revas-
cularization was superior to culprit lesion only PCI in
reducing the risk of cardiovascular death or myocardial
infarction, as well as the risk of cardiovascular death,
myocardial infarction, or ischemia-driven revasculariza-
tion, and benefits of complete revascularization were
observed regardless of whether complete revasculariza-
tion was performed during or after the index hospitali-
zation.10 , 11 Hence, complete revascularization of
hemodynamically stable STEMI patients is strongly
supported by recent evidence (Table I).12,13 However,
the optimal timing of revascularization of non-culprit
lesions in STEMI patients, i.e. immediate versus staged
PCI, remains a matter of ongoing debate.
The prospective, international, multicenter, random-
ized, two-arm, open-label MULTISTARS AMI (MULTi-
vessel Immediate versus STAged RevaScularization in
Acute Myocardial Infarction) trial is designed to investi-
gate whether immediate complete revascularization is
non-inferior to staged (within 19-45 days) complete
revascularization in stable patients with STEMI and MVD.Study objectives
MULTISTARS AMI is an investigator-initiated, prospec-
tive, international, multicenter, randomized, two-arm,
Figure 1
Study flow chart. PCI, percutaneous coronary intervention, STEMI, ST-segment elevation myocardial infarction.
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ate complete revascularization is non-inferior to staged
(within 19 – 45 days) complete revascularization after
successful primary PCI of the culprit coronary artery in
hemodynamically stable patients presenting with STEMI
and MVD. The trial is registered at www.clinicaltrials.gov
under NCT03135275.Study organization
The study organization of MULTISTARS AMI includes a
steering committee, a data safety monitoring board (DSMB),
and a clinical endpoints committee (CEC). The steering
committee is responsible for the scientific content of the
protocol, the management of the study, and the writing of
the manuscript. The study is monitored by an independent
DSMB and all clinical endpoints will be adjudicated by an
independentCEC.All study-relatedmeasures follow standard
operating procedures (SOPs) for study management,
monitoring, and data management.
MULTISTARS AMI is funded by the Investigator-
Sponsored Research Program of Boston Scientific Corpo-
ration (Marlborough, MA, USA; grant number
ISROTH10277). Boston Scientific Corporation has no
role in study design, data collection, analysis, monitoring,
and interpretation as well as writing of the manuscripts.
The authors are solely responsible for the design andconduct of the study, all study analysis, the drafting and
editing of publications, and their final content.
The first patient was included in January 2017, and in
June 2020, a total of 393 patients have been enrolled in
the study. Patient inclusion is planned to continue until
the end of 2021, and primary endpoints at 1 year should
be available for analysis by the end of 2022.
Patient population
A total of 840 patients with acute STEMI and MVD will
be enrolled at >30 sites in 4 countries (Switzerland,
Germany, Austria, and Italy). Randomization takes place
after successful primary PCI of the culprit artery to either
immediate or staged (within 19-45 days) complete
revascularization in a 1:1 ratio (Figure 1). Patients ≥18
years of age presenting with acute STEMI within 24 hours
of symptom onset and with MVD, defined as at least one
non-culprit coronary artery stenosis (≥70% luminal
diameter narrowing by visual estimate in at least two
projections) in a major epicardial coronary artery or
major branch (with a visually estimated lumen diameter
between 2.25 mm and 5.75 mm), are eligible for
enrollment. Only hemodynamically stable patients after
successful PCI of the culprit artery and with non-culprit
lesions suitable for PCI are included. Patients with stable
hemodynamics at the end of culprit artery PCI are eligible
for enrolment into MULTISTARS AMI. The definition of
Table II. MULTISTARS AMI inclusion and exclusion criteria
Inclusion criteria
Age ≥18 years
Patients with acute STEMI presenting within 24 hours of symptom onset
Suitability for PCI by transfemoral or transradial access
Identifiable culprit lesion
Coronary anatomy suitable for complete percutaneous revascularization
with the third-
generation, biodegradable-polymer, everolimus-eluting Synergy® stent
TIMI flow grade 2 or 3 after PCI of the culprit artery
Stable hemodynamics after PCI of the culprit artery
Non-culprit artery lesion with ≥70% diameter stenosis by visual estimation
in at least two
projections in a vessel with a lumen diameter of 2.25 – 5.75 mm
Exclusion criteria
Inability to give informed consent
Pregnancy at time of inclusion
Prior CABG
Pre-existing severe kidney disease (eGFR <30 ml/min/1.73 m2 or renal
replacement therapy)*
Prior allergic reaction to everolimus or any stent material
Cardiogenic shock
Prolonged resuscitation (>10 minutes)
Need for emergency CABG
Planned hybrid revascularization
Chronic total occlusion
Left main disease (>50% diameter stenosis) or left main equivalent
Coronary artery dissection
Stent thrombosis
In-stent restenosis
Mechanical complication of acute myocardial infarction
Planned coronary, cerebrovascular, or peripheral arterial revascularization
Planned cardiac or major surgery
Any contraindications for dual antiplatelet therapy for at least 90 days
(except for patients
on oral anticoagulation)
Life expectancy <1 year
CABG, coronary artery bypass grafting; eGFR, estimated glomerular filtration rate; PCI,
percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarc-
tion; TIMI, Thrombolysis In Myocardial Infarction. *when information on renal function
is available at the time of primary PCI.
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sion criteria of the CULPRIT-SHOCK (Culprit Lesion Only
PCI versus Multivessel PCI in Cardiogenic Shock) trial to
clearly separate the patient populations.14 Accordingly,
hemodynamic stability is defined as absence of systolic
blood pressure <90 mmHg, catecholamine therapy to
maintain systolic blood pressure >90 mmHg, and/or
clinical signs of hypoperfusion. Inclusion and exclusion
criteria are summarized in Table II.
In accordance with Good Clinical Practice guidelines and
as approved by the ethics committees, informed consent is
obtained with the use of a prespecified process. As soon as
coronary intervention is planned and the patient fulfills study
entry criteria, the patientwill be informed about the trial and
asked for written informed consent by the admitting
cardiologist. As patients are often not able to give written
informed consent in the acute STEMI setting, a study-specific
informed consent process was developed to avoid anytreatment delay. According to this process, patients who are
not able to provide written consent give oral informed
consent after successful primary PCI. An independent
physician not involved in the conduct of the study is witness
to the oral informed consent, which will be documented on
the informed consent form. When oral informed consent is
not possible in the acute STEMI setting, eg, due to conscious
sedation, the patient cannot be included in the study. After
the procedure, the patient confirms the oral consent by
signing the informed consent form.
Prospective registry
For patients who are pre-screened for the trial, but who
do not meet the inclusion criteria and do not enter the
trial, the reason for study exclusion is documented in a
parallel registry. This registry then allows for an
estimation of the proportion of screened patients
enrolled in the randomized trial.
Randomization and invasive procedures
After successful primary PCI of the culprit artery
according to current guidelines and using standard
techniques, patients are randomly allocated in a 1:1 ratio
to either immediate complete revascularization or staged
(19-45 days) complete revascularization (Table III). Patient
randomization is performed electronically via a secured
web-based electronic case report form (eCRF) system and
using block randomization to ensure equal numbers of
patients in both arms (secuTrial, interactive Systems
GmbH, Berlin, Germany). Variable block sizes are used to
reduce the predictability of the sequences.
In the immediate complete revascularization group,
PCI of all non-culprit lesions is performed immediately
after culprit artery PCI. In the staged complete revascu-
larization group, PCI of all non-culprit lesions is per-
formed within 19-45 days during a second procedure.
Percutaneous coronary revascularization is performed
with standard techniques and according to current
guidelines using the third-generation, biodegradable-
polymer, everolimus-eluting Synergy stent.15 ,16 The
choice of the access site is left at the discretion of the
operator. The use of FFR or intravascular imaging
including intravascular ultrasound (IVUS) and optical
coherence tomography (OCT) is left at the discretion of
the operator.15,16 Thrombus aspiration is performed and
glycoprotein IIb/IIIa inhibitors are administered in
accordance with contemporary guidelines and local
standards.17,18 Left ventricular function is assessed by
echocardiography during the index hospitalization. Dual
antiplatelet therapy is planned to be given for at least 90
days, preferably for 12 months following the index PCI,
with the exception of patients with any indication for oral
anticoagulation.17-19 In these patients, either triple or
dual antithrombotic therapy can be administered follow-
ing PCI. All patients receive optimal medical management
and secondary prevention according to current
Table III. MULTISTARS AMI data acquisition.
Screening Randomization Immediate PCI
of non-culprit
lesions
(Group 1)
Hospitalization and
discharge
Staged PCI of
non-culprit lesions
at 19-45 days
(Group 2)
Staged
hospitalization
and discharge
(Group 2)
FUP:
30-day*
(Group 1,
by visit
or phone)
FUP:
6-month
(by visit
or phone)
FUP:
1-year
(by visit)
Group 1
(“immediate
complete
revascularization”)
x x x x x x x
Group 2
(“staged complete
revascularization”)
x x x x x x x x
Informed consent x
In-/exclusion criteria x
Medical history x
Physical examination x x x x
Blood analysis x x x x
12 lead ECG x x x x x
Medication regimen x x x x x x x x x
Index procedure x
Randomization x
Transthoracic
echocardiography
x x
Adverse events,
primary and
s e c o n d a r y
endpoints
x x x x x x x
EQ-5D questionnaire x x x
Final status x
ECG, electrocardiogram; EQ-5D, EuroQol 5D; FUP, follow-up; PCI, percutaneous coronary intervention. *An additional follow-up 30 days after complete revascularization is
performed by visit or phone in Group 2.
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randomly assigned study treatment.Primary and secondary endpoints
Endpoint definitions are given in Table IV. The primary
endpoint is a composite of all-cause death, non-fatal
myocardial infarction, unplanned ischemia-driven revas-
cularization, hospitalization for heart failure, and stroke at
1 year.
Secondary endpoints (assessed at 6 months and 1 year)
include:
• Primary endpoint at 6 months
• Single components of the primary endpoint
• All-cause death or non-fatal myocardial infarction
• Procedural success
• Target vessel revascularization
• Target lesion revascularization
• Cardiac death
• Cardiovascular death
• Cardiac death or non-fatal myocardial infarction
• Stent thrombosis
• Acute renal insufficiency or renal replacement therapy• Bleeding events (categorized according to Bleeding
Academic Research Consortium [BARC] grades)
• Quality of life as assessed by the EuroQol 5D (EQ-5D)
questionnaire
Follow-up
Follow-up is performed at 30 days (corresponding to the
second hospitalization in the staged complete revasculariza-
tion group), 6 months, and 12 months after randomization.
According to the protocol, the 30-day follow-up in the
immediate complete revascularization group is performed
either by phone or visit at 30 days (+/- 1 week), resulting in
follow-up performed between 23-37 days after randomiza-
tion. The 30-day follow-up in the staged complete revascu-
larization group is performed for practical reasons during the
hospitalization for the staged procedure (after the interven-
tion), regardless of the timing within this window, resulting
in follow-up performed between 19-45 days after random-
ization. An additional follow-up at 30 days after the staged
procedure was incorporated into the visit schedule of the
staged complete revascularization group to assure equal
capturing of events up to 30 days after complete revascu-
larization in both groups. Both groups must have a visit or
telephone contact at 6 months (+/- 2 weeks) and one visit in
person at 1 year (+/- 2 weeks) after randomization.
Table IV. Outcome definitions.
Endpoint Definition
All-cause death All deaths due to cardiovascular and non-cardiovascular causes. All deaths with a clear cardiac or
unknown cause will be classified as cardiac. All deaths caused by non-coronary vascular causes
will be classified as vascular. Only deaths due to a documented non-cardiovascular cause
(e.g. trauma, cancer, suicide) will be classified as non-cardiovascular.
Myocardial infarction Myocardial infarction is defined based on the Third Universal Definition of Myocardial Infarction.
The term myocardial infarction should be used when there is evidence of myocardial necrosis in a
clinical setting consistent with myocardial ischemia. Under these conditions any one of the following
criteria meets the diagnosis for myocardial infarction:
1. Detection of a rise and/or fall of cardiac biomarkers (preferably cTn) with at least one value
above the 99th percentile of the URL and with at least one of the following:
a. Symptoms of ischemia
b. New significant ST segment alterations, T-wave changes, or new LBBB in the ECG
c. Development of pathological Q waves in the ECG
d. Imaging evidence of new loss of viable myocardium
e. Identification of an intracoronary thrombus by angiography
2. Cardiac death with symptoms suggestive of myocardial ischemia and presumed new ischemic ECG
changes or new LBBB, but death occurred before cardiac biomarkers were obtained, or before cardiac
biomarker values would be increased.
3. PCI-related myocardial infarction (MI type 4a): Elevation of cTn values >5 x 99th percentile occurring
within 48 hours of the procedure in patients with normal baseline values (≤99th percentile), or a rise of cTn
values >20 percent if baseline values are elevated or are stable or falling. In addition, either new or
aggravating prolonged (>20 min) symptoms suggestive of myocardial ischemia, or new persistent ischemic
ST segment changes or new pathological Q waves, or angiographic evidence of a flow-limiting complication
such as persistent occlusion or persistent slow-flow, no-reflow, or embolization, and/or angiographic evidence
of persistent loss of patency of a major (≥ 2.0 mm) side branch, or imaging evidence of new loss of viable
myocardium or new regional wall motion abnormality are required.
4. Stent thrombosis associated with myocardial infarction when detected by coronary angiography or autopsy
in the setting of myocardial ischemia and with a rise and/or fall of cardiac biomarker values with at least
one value above the 99th percentile URL.
5. For CABG, in patients with normal baseline cTn values (≤99th percentile URL), myocardial infarction is
arbitrarily defined by elevations of >10 x 99th percentile URL plus either new pathological Q waves or new
LBBB, or angiographic documented new graft or native coronary artery occlusion, or imaging evidence
of new loss of viable myocardium.
6. Pathological findings of an acute or a recent myocardial infarction.
A rise of cardiac enzymes post procedure represents an inherent condition in the course of a myocardial
infarction treated with primary PCI. Therefore, in case of new persistent ischemic ST segment changes or
new/aggravating prolonged (>20 min) symptoms suggestive of myocardial ischemia, within 48 hours of the
procedure, a coronary angiogram is recommended to confirm or exclude periprocedural myocardial infarction.
Ischemia-driven
revascularization
Ischemia-driven revascularization is defined as unplanned revascularization due to angina symptoms, new ischemic
ECG changes, or signs of reversible myocardial ischemia on non-invasive imaging.
It includes:
1. TLR or TVR.
2. PCI performed in the staged complete revascularization group between randomization and the planned
staged procedure for significant coronary lesions that were scheduled to be treated as staged, but which
instead were treated earlier due to symptoms or evidence of ischemia.
3. PCI of lesions not identified previously as significant.
4. CABG for new symptoms or complications of PCI.
Hospitalization for
heart failure
Hospitalization for heart failure is defined as hospital admission due to any of the following symptoms and
signs of heart failure: Dyspnea, fatigue, fluid overload, pulmonary edema, elevated venous pressure, and
elevated BNP or NT-pro BNP levels. Confirmation of heart failure according to local expert judgment will
be required for the event to be classified as heart failure.
Stroke The definition of stroke includes ischemic and hemorrhagic strokes. An ischemic stroke is defined as
new focal neurologic deficit that either results in clinical symptoms lasting for at least 24 hours or that is
associated with evidence of relevant infarction on CT scan or MRI of the brain. A hemorrhagic stroke is defined
as an acute focal neurologic deficit that is associated with the evidence of intracranial bleeding on CT or MRI of the brain.
BNP, brain natriuretic peptide; CABG, coronary artery bypass grafting; CT, computed tomography; cTn, cardiac troponin; ECG, electrocardiogram; LBBB, left bundle branch block;
MRI, magnetic resonance imaging; NT-pro BNP, N-terminal pro brain natriuretic peptide; PCI, percutaneous coronary intervention; TLR, target lesion revascularization; TVR, target
vessel revascularization; URL, upper reference limit.
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The following substudies will yield mechanistic insights
into effects of non-culprit artery PCI during the acute
phase of STEMI, although the study is not adequately
powered to draw firm conclusions in subgroups.
Coronary artery disease severity. The impact of
immediate versus staged complete revascularization may
vary according to coronary artery disease severity and
extent.20 Both the anatomical and functional SYNTAX
scores will be calculated by blinded observers. The
functional SYNTAX score will be calculated based on
angiography-derived quantitative flow reserve (QFR)
measurements of non-culprit lesions. Patients will then
be divided according to the SYNTAX scores and the effect
of immediate versus staged complete revascularization
compared across SYNTAX score groups. Further, the
impact of the residual SYNTAX scores on outcomes will
be investigated.
Left ventricular systolic dysfunction. Differential
effects of immediate versus staged complete revascular-
ization will be investigated based on left ventricular
systolic function at baseline. In patients with available
follow-up echocardiography, the impact of immediate
complete revascularization on left ventricular recovery
will be assessed.
Access site. This subproject allows for a comparison of
the safety and efficacy of immediate versus staged
complete revascularization in relation to radial versus
femoral access.
Kidney disease. Patients will be divided according to
baseline estimated glomerular filtration rate and the
impact of immediate versus staged complete revascular-
ization on post-procedural kidney function and outcomes
will be compared among groups.
Cost-effectiveness analysis. MULTISTARS AMI will
allow for a cost-effectiveness analysis according to
current standards. In this subproject, cost-effectiveness
of immediate versus staged complete coronary revascu-
larization will be assessed stratified to the different health
care systems in the participating nations.Sample size calculation
Sample size calculation was based on the primary
endpoint and the available evidence published to date.
Given the event rates reported in the most recent trials
with similar trial designs as MULTISTARS AMI (imme-
diate randomization at the time of primary PCI, similar
in-/exclusion criteria),8 , 9 sample sizes of 400 in each
group achieve 80% power to exclude a non-inferiority
ratio of 1.46 (R0).
21-24 The margin was based on the
expected rate of events in the staged complete
revascularization group and a prespecified judgment
about clinically meaningful difference. The power was
computed for the case where both the staged and theimmediate treatment group proportions are 18%, using
the one-sided Farrington-Manning score test with the
significance level targeted at 5%. Assuming a propor-
tion of 5% dropping out in both groups, a total of 420
patients are needed in each group. Altogether, a total of
840 patients will be sufficient.
Data analysis
Intention-to-treat analyses will represent the primary
analyses, with patients analyzed according to the random-
ized treatment allocation. As-treated analyses will be
performed as sensitivity analyses. Given the randomization
into either an immediate complete or a staged complete
revascularization group, crossovers may occur when the
randomized treatment allocation is not followed by the
operator, which is expected to occur infrequently.
Endpoints will be analyzed by calculating event rates
for the two groups counting the first occurrence of any
component of the composite outcome. Event rates will
be compared among groups using the one-sided
Farrington-Manning score test. In addition, endpoints
will be analyzed using a time-to-event approach. Kaplan-
Meier curves will be plotted for the time from random-
ization to the occurrence of the clinical outcomes and
comparisons between treatment arms performed by the
log-rank test. Cox proportional hazard models will be
fitted to estimate hazard ratios and 95% confidence
intervals for treatment comparisons. All testing will be
conducted at the 0.05 significance level. Non-inferiority
of immediate to staged complete revascularization will be
claimed if the upper limit of the one-sided 95%
confidence interval of the risk ratio will not cross the
prespecified non-inferiority margin. If non-inferiority can
be claimed, an additional superiority analysis on a two-
sided alpha of 0.05 will be performed.
Subgroup analyses of the primary endpoint will be
performed with pre-specified covariates including age,
sex, smoking status, history of myocardial infarction,
infarct location, number of coronary arteries with
stenosis, non-culprit artery stenosis severity, symptom
duration, ECG characteristics, concomitant medica-
tion, type and duration of dual antiplatelet therapy,
access site (radial versus femoral), lab values (including
estimated glomerular filtration rate), and presence of
co-morbidities such as diabetes, peripheral artery
disease, left ventricular ejection fraction, prior myo-
cardial infarction, and angina.
Ethical considerations
The protocol has been approved by the ethics
committees and the study is conducted according to
local laws and regulations and in compliance with the
Declaration of Helsinki. All sites receive extensive
training before study initiation. All safety aspects will be
monitored by an international DSMB (consisting of 3
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provided by the clinical trial sites, events will be
adjudicated by a CEC (consisting of 3 cardiologists
blinded to the patients’ assigned treatment).Discussion
Multivessel coronary artery disease is observed in about
half of STEMI patients and is associated with worse
outcomes compared with single vessel disease.1-4 Recent
randomized trials demonstrated superiority of complete
over culprit lesion only revascularization in hemodynam-
ically stable STEMI patients with MVD and resulted in a
class IIa recommendation for non-culprit lesion PCI in
this setting.6-10,17 Further, in two large meta-analyses, a
strategy of complete revascularization was associated
with an over 30% relative risk reduction in cardiovascular
mortality as compared with a strategy of culprit lesion
only PCI in patients with STEMI and multivessel disease
without cardiogenic shock at presentation.25,26
Optimal timing of non-culprit lesion PCI in STEMI
patients with MVD is not yet established, and whether
benefits of immediate complete revascularization out-
weigh related risks remains to be determined.13,27,28 On
the one hand, immediate complete revascularization may
limit infarct size due to increased collateral flow, and may
beneficially affect left ventricular remodeling by decreas-
ing recurrent myocardial ischemia due to obstructive
coronary artery lesions. Indeed, the observational Car-
diovascular Magnetic Resonance (CMR) substudy of
CvLPRIT suggested that immediate complete as com-
pared with staged complete revascularization was related
with smaller infarct size and improved left ventricular
systolic function.29 Given the diffuse inflammatory nature
of acute coronary syndromes, immediate complete
revascularization may further reduce rates of future
adverse events related to complex and vulnerable non-
culprit lesions.30-32 Complete revascularization at the
time of primary PCI has the advantage of exposing the
patient to a single arterial puncture and coronary
procedure and may be associated with lower health
care costs as prolonged hospital stay or second hospital-
ization can be avoided. On the other hand, immediate
complete revascularization of non-culprit lesions usually
requires longer procedural duration and a higher amount
of contrast agent, and may therefore entail an increased
risk of acute kidney injury and acute left ventricular
volume overload. Prolonged interventions during the
acute phase of STEMI, when both inflammation and
coagulation are activated to a maximal extent, may
further carry an increased risk of periprocedural compli-
cations. In CULRPIT-SHOCK, which enrolled a total of
706 acute myocardial infarction patients with MVD and
cardiogenic shock, the hazards of a prolonged procedure
and a higher amount of contrast agent in the complete
revascularization group seemed to outweigh the risks ofrepeat revascularization in the culprit-only revasculariza-
tion group.14,33
Data on the optimal timing of complete revasculariza-
tion in STEMI patients (during the same sitting or as a
staged procedure) remain conflicting. Real-world registry
data and post hoc analyses mostly reported a lower
mortality with staged complete revascularization in
STEMI patients.28,34-36 While a large network analysis
including over 40’000 patients from 4 prospective and 14
retrospective studies suggested superiority of staged over
immediate complete revascularization in patients with
STEMI and MVD,37 consistent benefits of complete
revascularization regardless of whether non-culprit lesion
PCI was performed in the same sitting or as a staged
procedure were demonstrated in a recent large meta-
analysis including 10 randomized controlled trials.25 The
meta-analysis of Pascerini et al showed that complete
revascularization performed during primary PCI was
associated with reduced rates of mortality and myocardial
infarction, whereas staged revascularization did not
improve these outcomes.13 In the only randomized trial
investigating the timing of complete revascularization in
STEMI patients published to date, similar rates of
cardiovascular events were observed in the immediate
and staged groups, although only limited conclusions can
be drawn from this study given the small sample size of 65
patients per group.38 In the randomized trials of
complete versus culprit lesion only revascularization in
STEMI, complete revascularization was either performed
exclusively during the same sitting,6 both during the
same sitting or as a staged procedure,7,9 or solely as
staged procedure,8,10,39 but comparisons among groups
were lacking. In COMPLETE, randomization was stratified
according to the intended timing of non-culprit lesion PCI
(as a staged procedure either during or after the index
hospitalization), and benefits of complete revasculariza-
tion were observed irrespective of the investigator-
determined timing of staged non-culprit lesion PCI.10,11
Randomized data on the timing of complete revascular-
ization in STEMI without cardiogenic shock at presenta-
tion are therefore warranted to determine whether
immediate non-culprit lesion PCI in the acute setting of
STEMI is non-inferior to a staged approach.
In line with previously published trials in this field and
current guidelines not recommending ad hoc PCI of
chronic total occlusions,6-8 the presence of a chronic
total occlusion was defined as exclusion criterion. While
some studies on complete coronary revascularization in
STEMI were based on angiography guidance,6,7 ,10 others
used functional lesion assessment for non-culprit lesion
revascularization.8,9 In accordance with COMPLETE,10
fractional flow reserve measurements for non-culprit
lesions with at least 70% diameter stenosis on visual
estimation are not mandatory according to the
MULTISTARS AMI protocol, but left at the discretion of
the operator, thus reflecting clinical practice according to
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analysis including randomized trials comparing complete
versus culprit lesion only revascularization in patients
with STEMI and MVD, no differential association with
treatment between angiography- and fractional flow
reserve-guided strategies on major cardiovascular out-
comes was observed.25 The time interval of 19 to 45 days
for staged PCI is in line with previous studies and allows
for a comparison of complete coronary revascularization
performed in an activated, inflammatory acute coronary
syndrome milieu with complete coronary revasculariza-
tion performed under stable conditions when the patient
has recovered from the acute phase of myocardial
infarction.38,40 Hence, the two selected time points of
complete revascularization represent distinct conditions
in the pathophysiological spectrum of coronary artery
disease, which may affect outcomes. The fact that the 30-
day follow-up in the immediate complete revasculariza-
tion group is performed either by phone or visit, while for
practical reasons it is performed during the second
hospitalization in the staged group, followed by a phone
call or visit at 30 days after the staged procedure, allows
for equal capturing of events up to 30 days after
completion of revascularization in any group. The two
30-day follow-ups in the staged group reflect the two
separate procedures, and any event occurring more than
30 days after complete revascularization in both groups
will be covered by the 6- and 12-month follow-up.
The definition of the primary endpoint, a composite of
all-cause death, non-fatal myocardial infarction, un-
planned ischemia-driven revascularization, hospitaliza-
tion for heart failure, and stroke at 1 year, is in line with
prior trials in patients with STEMI and MVD.(6-9) Non-
fatal myocardial infarction, ischemia-driven revasculariza-
tion, and hospitalization for heart failure are directly
related to the study intervention and represent clinically
meaningful adverse cardiac events.4,6-9 Stroke represents
a devastating cardiovascular complication following PCI,
with event rates being potentially affected by the
treatment allocation.9 The definition of myocardial
infarction includes both spontaneous and periprocedural
myocardial infarction and is classified based on the Third
Universal Definition of Myocardial Infarction.41 Although
the identification of periprocedural myocardial infarction
following primary PCI remains challenging, definitions
based on both elevated cardiac biomarkers and new clinical
signs and symptoms ofmyocardial ischemia should allow for
the detection of clinically-relevant events.
Among the ongoing studies comparing different revascu-
larization strategies in acute coronary syndrome patients
with MVD, only BioVasc (Direct Complete Versus Staged
Complete Revascularization in Patients Presenting With
Acute Coronary Syndromes and Multivessel Disease) –
similarly to MULTISTARS AMI – aims to investigate the
optimal timing of complete revascularization, i.e. immediate
versus staged PCI of non-culprit lesions, but enrolls not onlySTEMI but also non–ST-segment elevation myocardial
infarction (NSTEMI) patients. MULTISTARS AMI is, to the
best of our knowledge, the only ongoing trial testing the
hypothesis that in patients with STEMI andMVD, immediate
complete revascularization is non-inferior to staged com-
plete revascularization. MULTISTARS AMI will answer an
unresolved issue in coronary revascularization and further
define the optimal revascularization strategy in patients with
STEMI and MVD.
Summary
Despite the high prevalence and the worse outcomes of
patients with STEMI and MVD, the optimal timing of
complete revascularization has not yet been investigated
in a large-scale randomized study. The prospective,
international, multicenter, randomized, two-arm, open-
label MULTISTARS AMI trial is therefore designed to test
the hypothesis that in stable patients presenting with
STEMI and MVD, immediate complete revascularization is
non-inferior to staged complete revascularization.Acknowledgement
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